Millicent G. A. Bennett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Millicent G. A. Bennett has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Janna Leigh Morrison
University of South Australia
3 shared publications Ashley S. Meakin
2 shared publications- Dino A. Giussani
Department of Physiology, Development and Neuroscience University of Cambridge Cambridge UK
2 shared publications Kimberley J. Botting-Lawford
2 shared publicationsMichael D. Wiese
2 shared publicationsSage G. Ford
2 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by Elsevier in Pharmacological Research
- Vol. 231
Antenatal hypoxia and dexamethasone independently alter hepatic cytochrome P450 activity and glucocorticoid receptor isoform cellular localisation in ovine offspring
- 13 August 2026
- Published by Elsevier in Pharmacological Research
- Vol. 231
Open AccessAntenatal hypoxia and dexamethasone independently alter hepatic cytochrome P450 activity and glucocorticoid receptor isoform cellular localisation in ovine offspring
- Open Access
- 27 October 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 243 (Pt 1) , 117500
Chronic hypoxia or MitoQ treatment in pregnancy independently alter hepatic cytochrome P450 activity in fetal sheep and 9-month-old lambs
- 27 October 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 243 (Pt 1) , 117500
Open AccessChronic hypoxia or MitoQ treatment in pregnancy independently alter hepatic cytochrome P450 activity in fetal sheep and 9-month-old lambs
- Open Access
- 22 February 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (3) , 285
Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone
Background/Objectives: In pregnancy threatened by preterm birth, antenatal corticosteroids (ACS) are administered to accelerate fetal lung maturation. However, they have side effects, including the production of reactive oxygen species that can impact cytochrome P450 (CYP) activity. We hypothesised that antioxidants could protect a fetus treated with ACS during gestation and prevent the programming of altered hepatic CYP activity in the offspring. The primary outcome of our study was the impact of different maternal treatments on the activity of hepatic drug-metabolising enzymes in offspring. Methods: At 100 ± 1 days gestational age (dGA, term = 147 dGA), 73 ewes were randomly allocated to the following: saline (5 mL IV daily 105–137 ± 2 dGA, n = 17), ACS (Dexamethasone (Dex); 12 mg IM at 115 and 116 dGA; n = 25), MitoQ (6 mg/kg MS010 IV, daily bolus 105–137 ± 2 dGA; n = 17) or Dex and MitoQ (Dex+MitoQ; n = 14). CYP activity and protein abundance were assessed using functional assays and Western blot. Results: Dex decreased the hepatic activity of fetal CYP3A (−56%, PDex = 0.0322), and 9 mo lamb CYP1A2 (−22%, PDex = 0.0003), CYP2B6 (−36%, PDex = 0.0234), CYP2C8 (−34%, PDex = 0.0493) and CYP2E1 (−57%, PDex = 0.0009). For all, except CYP1A2, activity returned to control levels with Dex+MitoQ in 9 mo lambs. In 9 mo lambs, MitoQ alone increased activity of CYP2B6 (+16%, PMitoQ = 0.0011) and CYP3A (midazolam, +25%, PMitoQ = 0.0162) and increased CAT expression (PMitoQ = 0.0171). Dex+MitoQ increased CYP3A4/5 activity (testosterone, +65%, PIntx < 0.0003), decreased CYP1A2 activity (−14%, PIntx = 0.0036) and decreased mitochondrial abundance (PIntx = 0.0051). All treatments decreased fetal hepatic DRP1, a regulator of mitochondrial fission (PDex = 0.0055, PMitoQ = 0.0006 and PIntx = 0.0034). Conclusions: Antenatal Dex reduced activity of only one CYP in the fetus but programmed the reduced activity of several hepatic CYPs in young adult offspring, and this effect was ameliorated by combination with MitoQ.
- 22 February 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (3) , 285
Open AccessMaternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone
Background/Objectives: In pregnancy threatened by preterm birth, antenatal corticosteroids (ACS) are administered to accelerate fetal lung maturation. However, they have side effects, including the production of reactive oxygen species that can impact cytochrome P450 (CYP) activity. We hypothesised that antioxidants could protect a fetus treated with ACS during gestation and prevent the programming of altered hepatic CYP activity in the offspring. The primary outcome of our study was the impact of different maternal treatments on the activity of hepatic drug-metabolising enzymes in offspring. Methods: At 100 ± 1 days gestational age (dGA, term = 147 dGA), 73 ewes were randomly allocated to the following: saline (5 mL IV daily 105–137 ± 2 dGA, n = 17), ACS (Dexamethasone (Dex); 12 mg IM at 115 and 116 dGA; n = 25), MitoQ (6 mg/kg MS010 IV, daily bolus 105–137 ± 2 dGA; n = 17) or Dex and MitoQ (Dex+MitoQ; n = 14). CYP activity and protein abundance were assessed using functional assays and Western blot. Results: Dex decreased the hepatic activity of fetal CYP3A (−56%, PDex = 0.0322), and 9 mo lamb CYP1A2 (−22%, PDex = 0.0003), CYP2B6 (−36%, PDex = 0.0234), CYP2C8 (−34%, PDex = 0.0493) and CYP2E1 (−57%, PDex = 0.0009). For all, except CYP1A2, activity returned to control levels with Dex+MitoQ in 9 mo lambs. In 9 mo lambs, MitoQ alone increased activity of CYP2B6 (+16%, PMitoQ = 0.0011) and CYP3A (midazolam, +25%, PMitoQ = 0.0162) and increased CAT expression (PMitoQ = 0.0171). Dex+MitoQ increased CYP3A4/5 activity (testosterone, +65%, PIntx < 0.0003), decreased CYP1A2 activity (−14%, PIntx = 0.0036) and decreased mitochondrial abundance (PIntx = 0.0051). All treatments decreased fetal hepatic DRP1, a regulator of mitochondrial fission (PDex = 0.0055, PMitoQ = 0.0006 and PIntx = 0.0034). Conclusions: Antenatal Dex reduced activity of only one CYP in the fetus but programmed the reduced activity of several hepatic CYPs in young adult offspring, and this effect was ameliorated by combination with MitoQ.
- 1 April 2020
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 28, S32-S33
Development of a murine model to study mitochondrial transfer between mesenchymal stromal cells and injured chondrocytes
- 1 April 2020
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 28, S32-S33
Development of a murine model to study mitochondrial transfer between mesenchymal stromal cells and injured chondrocytes